The JAK-STAT pathway plays a pivotal role in the pathogenesis of myeloproliferative neoplasms (MPNs) including polycythemia vera, essential thrombocythemia, and myelofibrosis and JAK 1/2 inhibitors such as ruxolitinib have been vital in improving patient survival. The recent approval of ropeginterferon alfa-2b-njft, an interferon therapy for patients with polycythemia vera, and investigational combination therapies in myelofibrosis represent a new generation of therapies that aim to treat MPNs.
In this podcase, Ruben Mesa, MD, UT Health San Antonio MD Anderson Cancer Center, San Antonio, TX, and Naveen Pemmaraju, MD, University of Texas MD Anderson Cancer Center, Houston, TX, share valuable insights on MPNs, including the use of LSD1 inhibitor IMG7289 and ropeginterferon in the second line setting, as well as updates in the treatment landscape of polycythemia vera and myelofibrosis. This interview took place at the 63rd ASH Annual Meeting and Exposition Congress, Atlanta, GA, 2021.
The post ASH 2021: novel developments in MPNs appeared first on VJHemOnc.
